Title: Management of Initial Protocol Submissions

SOP Code: SOP 05/V5 dated 26th July 2017

Authors:

Dr. Sharmila Jalgaonkar (Member Secretary, IEC-I)

Dr. Snehalata Gajbhiye (Member Secretary, IEC-II)

Reviewed by:

Dr. Padmaja Marathe (Member, IEC-II)

Dr. Yashashri Shetty (Member, IEC-I)

Dr. Urmila Thatte (Member, IEC-I)

Approved by:

Dr. Padmavathy Menon, Chairperson, IEC - I
(Signature with Date)

Dr. Alan Almeida, Chairperson, IEC - II
(Signature with Date)

Table of Contents

<table>
<thead>
<tr>
<th>No.</th>
<th>Contents</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Purpose</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>Scope</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>Responsibility</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>Flow Chart</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>Detailed Instructions</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>Annexure</td>
<td>6</td>
</tr>
</tbody>
</table>
IEC will comply with following national and international guidelines which PI should also aware of

- Indian GCP
- (www.icmr.nic.in Ethical Guidelines for Biomedical Research on Human Participants, Indian Council of Medical Research, October 2006)
- Schedule Y and applicable recent regulatory notifications
- CDSCO guidelines (Central Drugs Standard Control Organization guidelines)
- Declaration of Helsinki

1. Purpose

The purpose of this Standard Operating Procedure (SOP) is to describe how the Secretariat of the Institutional Ethics Committee (IEC) manages protocol submissions to the IEC.

2. Scope

Initial submission will include submission of research protocol for Initial Review of the Protocol and related documents.

3. Responsibility

It is the responsibility of the IEC secretariat to verify eligibility of PI, receive the submission packages, ensure complete documentation, record receipt of the package and forward to the member secretary.

4. Flow chart

<table>
<thead>
<tr>
<th>No.</th>
<th>Activity</th>
<th>Responsibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Verify eligibility of Principal Investigator (PI) and completion of registration process on e-EC</td>
<td>IEC Secretariat</td>
</tr>
<tr>
<td>2</td>
<td>Receive Submitted Packages</td>
<td>IEC Secretariat</td>
</tr>
<tr>
<td>3</td>
<td>Verify submission as per checklist</td>
<td>IEC Secretariat</td>
</tr>
<tr>
<td>4</td>
<td>Allocation of protocols to member secretary for selection of Primary Reviewers (PR)</td>
<td>IEC Secretariat</td>
</tr>
<tr>
<td>5</td>
<td>Decision on type of review required and selection of primary reviewers</td>
<td>Member Secretary</td>
</tr>
<tr>
<td></td>
<td>a) Full Board Review (refer SOP 05-A)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Expedited Review (refer SOP 05-B)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>c) Exempt from Review (refer SOP 05-C)</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Distribute submission packages to reviewers</td>
<td>Member Secretary</td>
</tr>
</tbody>
</table>
5. Detailed instructions

5.1 Verify eligibility of PI and completion of registration process on e-EC

IEC secretariat will verify eligibility of PI by reviewing the information submitted by the PI (Refer Annexure 5 SOP 5):
Once registered PI can forward the project to IEC admin using e-EC software.
**Definition of Principal investigator (PI):** (as per policy decision 13 March 2014):
Principal investigator must be a faculty / employee of Seth G. S. Medical College and KEM Hospital and have appropriate post graduate qualification approved by respective statutory council.
For e-EC software submission only PI can forward the project to IEC.

5.2 Receive submitted packages

IEC admin will view and review the submission and will perform the actions against the project submission. Upon review of submission if application found to be complete IEC admin will enter with details of submission. IEC admin will then take the action depending on observations (Refer annexure 10 Guidance document for IEC Admin)

5.3 Initial Review Application

5.3.1 Check for submission items

- The Secretariat will check the soft copies of all types of studies and hard copy for regulatory studies (1 hard copy for non-regulatory studies if needed) of following items

1. A completely filled IEC Project Submission Application Form for Initial Review AX 1-A/SOP 05/V5 & AX 1-B/SOP 05/V5
2. A checklist for contents of a submitted package and list of the documents uploaded for submission via e-EC software AX 02/SOP 05/V5
3. Delegation of Responsibilities of Study team AX 03/SOP 05/V5
4. Document Receipt Form AX 04/SOP 05/V5

5.3.2 Verify submission as per checklist

The Secretariat will:

- Use the checklist for contents of a submitted package, AX 02/SOP 05/V5 to verify that items listed and ticked in the checklist are present in the package.
- Check if all relevant and applicable forms and documents are in the submitted package being submitted to the IEC office. The correctness of the IEC application form will be assessed at the time of submission by the secretariat. Verify the completeness of the contents of the protocol submitted package to include the following documents:
  - Project submission application form for initial review
  - Letter to Member Secretary/ Chairperson
  - Protocol, to include
Management of initial Protocol Submissions

a) Title of the Protocol
b) Name and contact details of Principal Investigator
c) Name and contact details of Sponsor
d) IND Number (if applicable)
e) Abstract (summary/synopsis)
f) Study Methodology - Type of Protocol (screening, survey, phase of clinical trial), Objectives, Inclusion/Exclusion Criteria, Withdrawal or discontinuation Criteria, Schedule and Duration of Treatment, Modes of Treatment Studied, Procedures, Activity plan / Timeline, Efficacy or Evaluation Criteria (Response/Outcome), Safety Parameters Criteria (Toxicity), Analysis (methods)

✓ Amendments to protocol (if any)
✓ Informed consent document in English (as per sample format in Annex AX 06/SOP 05/V5)
✓ Informed consent document in Regional languages (Hindi & Marathi)
✓ Back translations of Informed consent documents
✓ Translation and Back translation certificate
✓ Informed Consent Document (ICD) or Amendments to the Informed consent document (if any)
✓ Case Record Form
✓ Recruitment procedures: advertisement, notices, letters to doctors ?? (if applicable)
✓ Patient instruction card, identity card, diary etc. (if applicable)
✓ Investigator Brochure
✓ Regulatory permissions (as applicable)
  ➢ DCGi approval
  ➢ Investigator’s Undertaking to DCGI
  ➢ FDA marketing/manufacturing license for herbal drugs
  ➢ Health Ministry Screening Committee (HMSC) approval
  ➢ Bhabha Atomic Research Centre (BARC) approval
  ➢ Genetic Engineering Advisory Committee (GEAC) approval
  ➢ A copy of Administrative sanction from the head of the Institution for sending the samples to laboratories outside KEM Hospital.
✓ Departmental Review Board approval letter (Thesis / Dissertations)
✓ Current signed and dated Brief Curriculum Vitae of all the study team members
✓ GCP training certificate (within 3 years) of Principle investigator and study team members.
✓ Investigator’s agreement with Sponsor
✓ Memorandum of Understanding (MOU) between collaborative institutions (On Rs 100 stamp paper, tripartite with terms of agreements specified clearly)
✓ Sanction letter for central government funding bodies
Management of initial Protocol Submissions

✓ Entire Insurance policy with certificate
✓ Ethics Committee clearance of other centers (if applicable)
✓ Institutional Stem cell committee approval (if applicable)
✓ Any additional document(s), as required by IEC (Cheque/ Demand Draft drawn in the name of “Diamond Jubilee Society Trust, Seth GS Medical College and KEM Hospital” towards payment of IEC processing fees, as decided upon by the IEC from time to time)

5.4 Complete the submission process

- IEC Admin Review Actions

Upon Review of submission IEC Admin may choose one of the following action depends on his observations.

- Forward (to IEC MS)

  The Administrative Officer/ any one designated by IEC will

If online application found to be complete, IEC Admin will enter following details (depends on submission type):

✓ Processing Fee Paid (Yes/No)
✓ Hard copy of project documents submitted (Yes/No)

Stamp the receiving date on the first page/last page of the covering letter, on the first page of received documents and IEC admin will assign the inward number for hard copies.

✓ Reviewed by (IEC Staff / Admin Name, signature and date)
✓ Project Number (textbox for entering allotted Project Number)

The project number will be assigned by the IEC admin as per following submission types:

The project file as EC/PHARMA Number (00)/ year (00) for pharmaceutical sponsored studies and EC/GOVT Number (00)/ year (00) for Government/ Government-agency sponsored studies, EC/Number (00)/year (00) for thesis and EC/OA Number (00) for non-sponsored / OA-Other Academic studies e.g. EC/PHARMA 01/07 will indicate pharmaceutical sponsored study with number 01 of the year 2017.

Insurance Date (Renewal)

Stamp the receiving date on the first page/last page of the covering letter, on the first page of received documents and IEC admin will assign the inward number for hard copies.

Keep the copies of the submitted documents with original signatures in the protocol “Submission” file.

Each Pharma sponsored, government sponsored and academic projects are alternatively distributed to either IEC-I or IEC-II member secretaries for the further actions.

- Return (to PI)

  The incomplete submissions will be return back to the respective investigator with mentioning
reason for the same.

5.5 Saving / Storage packages
The Administrative Officer will save the submissions which will be stored separately for IEC-I & II as follows:
1) E-EC software cloud based
2) Google drive
3) External Hard disk

The submitted hard copy protocols and the related documents will be labeled and stored in cupboard with lock and key in separate cupboard of IEC-I & II.

Decision on type of review:
Member secretary will review the protocol and related documents and will take the decision regarding the type of the review required for the particular protocol as follows:

a) Full Board Review (refer SOP 05-A/V5)

b) Expedited Review (refer SOP 05- B /V5)

c) Exempt from Review (refer SOP 05-C/V5)

5.4 Appointment of primary reviewers

• The Member Secretary/Chairperson will appoint one or more primary reviewers for each project on the basis of expertise in the related field and experience. The Secretariat will forward the protocol and related documents to IEC Members for initial review

6. Annexure

Annexure 1-A AX 01-A/SOP 05/V5 Project submission application form for initial review for Industry and Government sponsored studies.

Annexure 1-B AX 01-B/SOP 05/V5 Project submission application form for initial review for all academic (non sponsored) studies.

Annexure 2 AX 02/SOP 05/V5 Checklist of protocol submission

Annexure 3 AX 03/SOP 05/V5 Delegation of Responsibilities of Study team

Annexure 4 AX 04/SOP 05/V5 Document Receipt Form

Annexure 5 AX 5/SOP 05/V5 Guidelines for Investigators

Annexure 6 AX 06/SOP 05/V5 Sample format of an Informed Consent Document

Annexure 7 AX 07/SOP05/V5 Sample Format of an Assent to be a Participant in a Research Study (For Children between 7-18 years old) in English
Annexure 8  AX 08/SOP 05/V5  Format for submission of an Informed Consent Document for Genetic Studies

Annexure 9  AX 09/SOP 05/V5  Departmental Review Board (DRB) Guidance Document

Annexure 10  AX 10/SOP 05/V5  Guidance document for IEC Admin

---

### Annexure 1-A

**AX 1-A/SOP 05/V5**

**Project submission application form for initial review for Industry and Government sponsored studies**

- Please fill in the details in legible hand writing
- Tick √ in the box for the appropriate answer
- Tick/ Write NA if question is not applicable

<table>
<thead>
<tr>
<th>IEC Protocol No.</th>
<th>Submission date:</th>
</tr>
</thead>
</table>

**Title of the protocol**

__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________

<table>
<thead>
<tr>
<th>Name</th>
<th>Designation &amp; Qualifications</th>
<th>Department &amp; Institution</th>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Principal Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**“Principal investigator must be a faculty / employee of Seth G. S. Medical College and KEM Hospital and have appropriate post graduate qualification approved by respective statutory council”**.

(If additional collaborators attach details and letter of Consent by the collaborator(s) on a separate page.)

Please attach brief curriculum vitae of the study team members (principal investigator, co-investigator, study coordinator)

**Non-sponsored study**  [ ]  **Sponsored study**  [ ]

1. **Sponsor Information** :
   - 1. Indian  
     - a) Government  [ ]  Central  [ ]  State  [ ]
     - b) Private  [ ]
   - 2. International  [ ] Government  [ ] Private  [ ]  N agencies  [ ]
   - 3. Industry  [ ] National  [ ] Multinational  [ ]

**Contact Address of Sponsor:**
________________________________________________________________________

If sponsor is from out of India, contact address in India:
________________________________________________________________________

2. **Total Budget** : Rs._______________
Research Fund will be deposited in: DJST □ DDF □ Research Society □ MRU

Other □ If other, please specify________________________________________________________

Please give details of allocation of budget in an attachment. Attached

Type of Study:  Epidemiological □ Basic Sciences □ Animal studies □ Any Other □

Please specify________________________________________________________________________

Clinical: Single center ____ Multicentric ____ (Attach a list of centers)
If multicentric, how many centres: India _____ and Globally: ____ (attach list of countries)

3. Clinical Trials:

**Medicine/Vaccines/Device/Herbal Remedies:** (Tick the appropriate boxes)

i. Does the study involve use of:

- Medicine □ Devices □ Vaccines □
- Indian Systems of Medicine/ □ Any other □ NA □

If other, specify______________________________________________________________

ii. Is it approved and marketed

- In India □ UK & Europe □ USA □ NA □
- Other countries, specify_________________________________________________________

(Tick the appropriate box/option)

iii. Does it involve a change in use, dosage, route of Administration?

- If yes, whether DCGI’s /Any other Regulatory authority’s Permission is obtained?

- If yes, Date of permission:____________

- If No, whether DCGI’s /Any other Regulatory Authority’s Permission applied for?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

iv. Is it an Investigational New Drug (IND)?

- If yes, IND No:

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a) Investigator’s Brochure submitted

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Institutional Ethics Committee (IEC)
**Seth G.S. Medical College and K.E.M. Hospital,**
Parel, Mumbai – 400 012.
Web: [www.kem.edu](http://www.kem.edu)

**Management of initial Protocol Submissions**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>b) <em>In vitro</em> studies data</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>c) Preclinical Studies done</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>d) Clinical Study is: Phase I</td>
<td>Phase II</td>
<td>Phase III</td>
</tr>
<tr>
<td>e) To submit package insert in case test drug is already marketed in India</td>
<td>Attached</td>
<td></td>
</tr>
</tbody>
</table>

- **Yes**
- **No**
- **NA**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>e) Are you aware if this study/similar study is being done else where?</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

**If Yes,** Specify details -------------------------------------------

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>f) Whether DCGI’s permission for testing IND obtained?</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>g) Whether DCGI’s permission for testing IND applied for?</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>h) For Ayurvedic or herbal formulation, a copy of the marketing/manufacturing license issued by the FDA to the company to be submitted</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

- **4. Protocol of the proposal** — Introduction, review of literature, aim(s) & objectives, justification for study, methodology describing the potential risks & benefits, outcome measures, statistical analysis and whether it is of national significance with rationale
  (Submit as attachment)

- **5. Research participants selection:**

  i. Number of research participants at this centre:

  Number of research participants at other sites in India:

  Total number of research participants at all sites (in the world):

  ii. Duration of study:

  No. of visits:

  iii. Will research participants from both sexes be recruited | Yes | No | NA |

  iv. Inclusion / exclusion criteria given | Yes | No |

  v. Type of research participants | Volunteers | Patients | NA |
vi. **Vulnerable research participants**

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
</table>

(Please refer to SOP no 20/V 5)

- pregnant women
- elderly
- mentally challenged
- fetus
- illiterate
- handicapped
- children
- captives
- terminally ill
- elderly
- seriously ill
- economically or socially backward
- dependent staff
- institutionalized employees
- students
- HIV
- Prisoners
- Any other

To specify _____________________________________________________________

Relevant Annexure filled

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

6. **Privacy and confidentiality**

i. Study involves -

<table>
<thead>
<tr>
<th>Direct Identifiers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Indirect Identifiers/coded</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Completely anonymised/ delinked</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Confidential handling of data by staff</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

7. **Use of biological/ hazardous materials**

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
</table>

i. Use of fetal tissue or abortus

<table>
<thead>
<tr>
<th>Use of organs or body fluids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

iii. Use of recombinant/gene therapy

<table>
<thead>
<tr>
<th>If yes, has Department of Biotechnology (DBT) approval for DNA products been obtained?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

iv. Use of pre-existing/stored/left over samples

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
</table>

v. Collection for banking/future research

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
</table>

vi. Use of ionizing radiation/radioisotopes

<table>
<thead>
<tr>
<th>If yes, has Bhaba Atomic Research Centre (BARC) approval for radioactive isotopes been obtained?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

### Management of Initial Protocol Submissions

**Vii. Use of Infectious/biohazardous specimens**

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
</table>

**Viii. Proper disposal of material**

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
</table>

### 8. Will any sample collected from the patients be sent abroad?

- **Yes**
- **No**
- **NA**

If yes:

a) Sample will be sent abroad because (Tick appropriate box):

- Facility not available in India
- Facility in India inaccessible
- Facility available but not being accessed.

If so, reasons: ____________________________

Lab. Address: ____________________________________________

If no:

b) test on samples be carried out:

- In KEM
- Outside KEM

If outside KEM, Address: ________________________________

If Yes, specify with details of collaborators

### 9. Is the proposal being submitted for clearance from Health Ministry’s Screening Committee (HMSC) for International collaboration? (required in case of studies involving collaborations with foreign Laboratory/ Clinic/Institution)

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
</table>

### 10. In case of studies involving collaborations with other Indian or foreign Laboratory/ Clinic/Institution has administrative sanction from the Dean obtained/ applied for?

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
</table>

### 11. Consent:

- *Written
- Oral
- Audio-visual

i. Consent form : (tick the included elements)

- Understandable language
- Alternatives to participation
- Statement that study involves research
- Confidentiality of records
- Sponsor of study
- Contact information
### Purpose and procedures
- Statement that consent is voluntary

### Risks & Discomforts
- Right to withdraw

### Benefits
- Compensation for study related injury

### Compensation for participation

### Benefits if any on future commercialization
- NA

### Consent for future use of biological material
- NA

*If written consent will not be obtained, give reasons: ____________________________

### Whether applied for waiver of Consent: ____________________________

#### ii. Who will obtain consent?
- PI/Co-PI
- Nurse/Counselor
- Research staff
- Any other

### 12. Will any advertising be done for recruitment of research participants? (posters, flyers, brochure, websites – if so kindly attach a copy)
- Yes
- No
- NA

### 13. Risks & Benefits:

#### i. Is the risk reasonable compared to the anticipated benefits to research participants / community / country?
- Yes
- No
- NA

#### ii. Is there physical / social / psychological risk / discomfort?
- If Yes, Minimal or no risk
- More than minimum risk
- High risk

#### iii. Is there a benefit
- (a) To the research participants? Direct Indirect
- (b) Benefit to society

### 14. Data Monitoring

#### i. Is there a data & safety monitoring committee/ Board (DSMB)?
- Yes
- No
- NA

#### ii. Is there a plan for reporting of adverse events?
- Yes
- No

If Yes, reporting is done to:
- Sponsor
- IEC
- SMB

#### iii. Is there a plan for interim analysis of data?
- Yes
- No
- NA

#### vi. Are there plans for storage and maintenance of all trial data?
- Yes
- No
<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
</tr>
</thead>
<tbody>
<tr>
<td>15. Is there compensation for participation</td>
<td>Yes</td>
<td>No</td>
<td>NA</td>
</tr>
<tr>
<td>If Yes, Monetary ☐ In kind ☐</td>
<td>Specify amount and type:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16. Is there compensation for injury?</td>
<td>Yes</td>
<td>No</td>
<td>NA</td>
</tr>
<tr>
<td>If Yes, by Sponsor ☐ Investigator ☐</td>
<td>by insurance ☐ any other company</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17. Do you have any conflict of interest in the present study?</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>(financial/non financial)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If Yes, specify:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18. Number of protocols handled by the PI at present including</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>current Status of ongoing studies approved by IEC or IEC carried out</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>by the Principal Investigator.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regulatory ☐ Non regulatory ☐</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Information to be given: IEC project registration no., whether study</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>is initiated, no. of approved research participants, no. of research</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>participants enrolled, no. of active research participants, no. of</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>research participants who have completed the study and total duration</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>of the study. Describe briefly in a separate sheet, if required)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19. Current Brief Curriculum Vitae (signed and dated copy) of the</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>study team members- principal investigator, co-investigator and study</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>coordinator. (Information required - age, designation and department,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>educational qualification, previous research experience in last two</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>years) (Information about GCP training of PI and co investigator)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20. GCP training certificates of study team members</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(To be enclosed along with the form)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21. Is the trial registered with Clinical Trial Registry? (mandatory</td>
<td>Yes</td>
<td>No</td>
<td>NA</td>
</tr>
<tr>
<td>only for drug trials) Clinical Trial Registry of India(CTRI)/ any other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHO platform registry</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Registration number:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If not registered, state the</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Statement of Compliance:

We hereby declare that the information given above is true and that we will comply with the guidelines mentioned in the Schedule Y (Drugs and Cosmetic Act 1940; amendment 20th January 2005, 30th January 2013, 8th February 2013), Ethical Guidelines for Biomedical Research on Human Participants by Indian Council of Medical Research (2006), Indian GCP Guidelines (2001) and the International Conference on Harmonisation - Good Clinical Practices (ICH-GCP) Guidelines (1996) while conducting the research study.

We also ensure that Principal Investigator / Institution will pay for treatment and / or compensation if study related injury occurred due to protocol violation by PI / study team.

Signature of Principal Investigator with date: ____________________

Signature/s with date of Co-investigators: 1.________________

2.________________ 3.________________ 4.________________ 5.________________

Signature of coordinator: 1.________________________ 2._____________________

Forwarded by Heads of Department(s)

Signature/s with date of Heads of Department(s):
________________,  __________________,  __________________,  __________________

________________,  __________________,  __________________,  __________________

Stamp/Seal of the Department(s)

Annexure 1-B

Project submission application form for initial review for all academic (non-sponsored) studies.

Please fill in the details in legible hand writing

Tick √ in the box for the appropriate answer/ Write NA if question is not applicable
### IEC Protocol no. _________________

**Title of the project**

__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________

<table>
<thead>
<tr>
<th>Name</th>
<th>Designation</th>
<th>Department and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Principal Investigator**

<table>
<thead>
<tr>
<th>Name</th>
<th>Designation</th>
<th>Department and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Co-Investigator**

<table>
<thead>
<tr>
<th>Name</th>
<th>Designation</th>
<th>Department and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Co-Investigator**

<table>
<thead>
<tr>
<th>Name</th>
<th>Designation</th>
<th>Department and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Co-Investigator**

<table>
<thead>
<tr>
<th>Name</th>
<th>Designation</th>
<th>Department and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Co-Investigator**

<table>
<thead>
<tr>
<th>Name</th>
<th>Designation</th>
<th>Department and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Principal investigator must be a faculty / employee of Seth G. S. Medical College and KEM Hospital and have appropriate post graduate qualification approved by respective statutory council*.

If additional collaborators attach details and letter of consent by the collaborator(s) on a separate page.

<table>
<thead>
<tr>
<th>Non-sponsored study</th>
<th>Sponsored study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If Non-Sponsored Study:

- Type of study: Thesis/dissertation  
- ICMR/KVPY
- Other Academic

Duration of study _______________________  
Approx. Completion date (MM/YY) _____________
If sponsored,
Total Budget : Rs.______________

From where is the study being funded

a) Research fund is being utilized from  
   DJST  [ ]  search Society  [ ]  MRU  [ ]

   Others  [ ]  If any other, please give details
   ___________________________________________

1. Type of Study :  [ ]  Prospective  [ ]  Retrospective  [ ]  Cross-sectional  [ ]

   Is the study observational/ Interventional? _____________________________________________________________________
   If interventional, does the study involve any deviation from routine/standard practices?
   ___________________________________________

2. Does the study involve use of :  Drug / Vaccine  [ ]  Device  [ ]  Alternative Medicine  [ ]
    
    New Technique (surgical/PT/OT, etc)  [ ]  Diagnostic Kit/ Investigations  [ ]

    If other, please specify
   ___________________________________________

   i) Is the test drug / device marketed in India  [ ]  Yes  [ ]  No  [ ]
   ii) Does the test drug involve a change in use, dosage, route of administration?

    [ ]  Yes  [ ]  No

    If yes, data generated intended for submission to licensing authority  [ ]  Yes  [ ]  No

    If yes, please attach copy of DCGI permission.

    If no, please attach copy of package insert/product insert.

3. Subject selection:

   i) Number of subjects at this centre  [ ]  if multicentric, total number of subjects  [ ]
ii) Vulnerable subjects   Yes ☐ No ☐ (If yes, tick the appropriate boxes)
(Please refer SOP no 20/v5)

- pregnant women ☐ illiterate ☐ seriously/terminally ill ☐
- children ☐ neonates ☐ mentally challenged ☐
- elderly ☐ handicapped ☐ economically/socially backward ☐
- institutional employees / students ☐ any other ☐
If other, please specify ____________________________________________________________________

Relevant annexures filled   Yes ☐ No ☐

4. Does the study involve use of
   i) fetal tissue or abortus
      Yes ☐ No ☐
   ii) organs or body fluids
      Yes ☐ No ☐
   iii) Gene therapy
      If yes, please submit a copy of Genetic Engineering Advisory Committee (GEAC) permission.
      Yes ☐ No ☐
   iv) ionizing radiation/radioisotopes
      If yes, please submit a copy of Bhabha Atomic Research Centre (BARC) Permission.
      Yes ☐ No ☐
   v) infectious / biohazardous specimens
      Yes ☐ No ☐
   vi) Will pre-existing/stored/left over samples be used?
      Yes ☐ No ☐
   vii) Will samples be collected for banking/future research
      Yes ☐ No ☐
   viii) Will any sample collected from patient be sent abroad?
      If yes, please submit a copy of Director General of Foreign Trade (DGFT) permission.
      Yes ☐ No ☐
<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>ix) Is there any collaboration with any foreign lab., clinic or hospital?</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>If yes, please submit a copy of Health Ministry Screening Committee (HMSC) approval.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Will any advertising be done for recruitment of Subjects? (Posters, flyers, brochures, etc.) If yes, kindly attach a copy for IEC review.</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>6. Is there compensation for participation (traveling allowance)? Yes ☐ No ☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>If Yes, Monetary ☐ In kind ☐ Specify amount / type: ____________________________</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Are there any arrangements for compensation / treatment of trial related injury? Yes ☐ No ☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>If yes, by sponsor ☐ by investigator ☐ By insurance company ☐ by others ☐ Please submit a copy of the insurance policy if it is available.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
8. Do you have any conflict of interest in the present study?

(financial / non – financial/ any other)

If yes, specify: ……………………………………………………………………………………

9. Is any other department involved in participant recruitment/investigation, but not co-investigators or collaborators? Yes/No

If yes, specify ………………………………..

Name and signature of concerned HOD ………………………………………………………………………………………………………………….

We hereby declare the information given above is true. A copy of the study report will be submitted at the end of the study.

Signature of Principal Investigator: ____________________________

Signatures of Co-investigators: 1._____________________ 2.___________________
3.____________________ 4. ___________________

Forwarded by Heads of Department(s) _____________________

Stamp/Seal of the Department(s)

Please fill the form in legible handwriting or type the information.

Write ‘Not Applicable’ (NA) wherever necessary.

Incompletely filled form will not be accepted.

Annexure 2

AX 02/SOP 05/V5

Check List for Protocol Submission

Check List of Documents for Protocol Submission to the Institutional Ethics Committee to be filled in by the study team

Protocol submission for initial review
(Tick accordingly, compulsory documents have to be submitted by ticking in the box marked as 'Yes') * Compulsory documents for initial review.

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Document</th>
<th>Yes</th>
<th>No</th>
<th>Date by which it will be submitted, if pending</th>
<th>NA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>*Project submission application form duly filled</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Approval of Departmental Review Board (DRB) (for thesis/dissertations proposals)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>*Letter to Member Secretary/ Chairperson</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>*Summary of protocol (in not more than 500 words)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>*Protocol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>*Informed consent document in English,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>*Informed consent documents in Regional languages (Total No:- ) Hindi, Marathi</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Back translation of Informed Consent Documents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Translation and Back translation certificates</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>*Case Record Form</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>*Research participants recruitment procedures: advertisement, notices (If applicable)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>*Patient instruction card, identity card, diary etc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>*Research participants Questionnaire/s (If applicable)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>*Investigator Brochure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>*Entire Insurance policy with certificate (applicable for interventional studies)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Undertaking by Principal Investigator regarding compensation for study related</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Requirement</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>*Investigator’s undertaking to DCG(I)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>DCG(I) approval [if DCGI approval is awaited, the application to DCGI needs to be submitted]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>*Clinical Trial Agreement for drug trial / Memorandum Of Understanding, as applicable, for collaborator &amp; Govt sponsored trials (draft if final not ready)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Final MOU: On Rs 100/- stamp paper, tripartite with terms of agreements specified clearly)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>FDA marketing/manufacturing license for herbal formulations/ nutraceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Bhabha Atomic Research Centre (BARC) approval in case study involves use of radioisotopes/ ionizing radiations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Genetic Engineering Advisory Committee (GEAC) approval in case study involves use of gene therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Administrative sanction from the Head of the Institution for the samples to be sent to outside KEM Hospital (one copy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>For non-collaborative and non-regulatory studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td><em>Signed and dated</em> brief current curriculum vitae of the entire study team members. (for regulatory studies and for non regulatory if needed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Valid MMC registration certificate of medical faculty</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td><em>Ethics Committee clearance of other centers (Total No ____</em>)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>*Log of delegation of responsibility of the study team members - Annexure3-SOP5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>*Document Receipt Form (Annexure4-SOP5 for regulatory studies and for non regulatory if needed )</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>*Current Status of Ongoing Studies approved by IEC and conducted by principal investigator (Attach separate sheet including information as Project registration number, title, no of participant approved by IEC, no of participants recruited, SAE at the site )</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Documentation of CTRI registration/ any other WHO platform registry (whenever applicable)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>*GCP training certificates of study team members (last 3years, for regulatory studies and for non regulatory if needed )</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>HMSC permission for International collaboration (required in case of studies involving collaborations with foreign Laboratory/ Clinic/Institution)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>Any other Documents submitted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

To be filled in by the IEC – Checklist for EC form:

1. Contact Address of Sponsor  
2. Total Budget  
3. Information on Clinical Trials  
4. Information on Protocol of the proposal  
5. Research participants selection  
6. Privacy and confidentiality  
7. Use of biological/ hazardous materials  
8. Consent  
9. Risks & Benefits  
10. Data Monitoring  
11. Compensation for participation  
12. Compensation for injury  
13. Statement on conflict of interest
Annexure 3

AX 03/SOP 05/V5

Delegation of Responsibilities of Study team

Date: _____________________

Study Title

__________________________________________________________________________

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Principal Investigator</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Co-investigator</td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Co-investigator</td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>Study co-ordinator *</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Study co-ordinator *</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Laboratory Technician</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
</tr>
</tbody>
</table>

* Study coordinator may preferably be a person specifically appointed for coordinating the clinical trial; other than the staff member (assistant / associate professor)

(Please place tick marks against assigned duties for each member in the following table)

<table>
<thead>
<tr>
<th>Code</th>
<th>TASKS</th>
<th>Role 1</th>
<th>Role 2</th>
<th>Role 3</th>
<th>Role 4</th>
<th>Role 5</th>
<th>Role 6</th>
<th>Role 7</th>
<th>Role 8</th>
<th>Role 9</th>
<th>Role 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>All relevant documents pertaining to protect blinding</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>Research participants selection/Screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>Obtain informed consent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>Evaluate inclusion/exclusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Criteria</td>
<td>Description</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E</td>
<td>Conduct the visit assessments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>Physical examination</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>Complete the source documents</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H</td>
<td>Complete Case Record Form</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>Final review and sign Case Record Form</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J</td>
<td>Collect laboratory safety test samples</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>K</td>
<td>Processing of blood samples</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L</td>
<td>Preparing aliquots &amp; keeping a track of the samples sent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>Review &amp; sign of the lab reports</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>Receive the study drug, document drug dispensing, storage &amp; accountability</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O</td>
<td>Person to whom research participants should contact in case of adverse event</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td>Report all serious adverse events</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q</td>
<td>Follow up of Serious Adverse Event</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R</td>
<td>Maintaining study site master file</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S</td>
<td>In-charge of inventory &amp; supplies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T</td>
<td>Archiving of study documents</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U</td>
<td>Resolution of queries</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V</td>
<td>Overall coordination and supervision</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Signature with date of Principal Investigator: __________________________
Annexure 4  
AX 04/SOP 05/V5

Document Receipt Form for initial review

<table>
<thead>
<tr>
<th>Protocol Number:</th>
<th>Received number:</th>
<th>Project Submitted date:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Protocol Title:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Department</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Communication with the IEC:</th>
<th>E-mail address</th>
<th>Phone</th>
<th>Fax</th>
</tr>
</thead>
</table>

**For office use only**

Documents submitted: □ Complete □ Incomplete, will submit on..........  

Documents to be submitted later:  
□ final signed clinical trial agreement with final budget allocation  
□ informed consent form (Local 3rd Vernacular language)  
□ DCGI  
□ CTRI  
□ Other sites EC permission  
□ Others..........................  

Check what documents are received later on.  
□ final signed clinical trial agreement with final budget allocation  
□ informed consent form (Local 3rd Vernacular language)  
□ DCGI  
□ CTRI  
□ Other sites EC permission  
□ Others..........................  

Received by (Name and signature) :  

Date on which documents received:  

Note:
For e-EC initial submission investigator will receive an acknowledgement email instead of document receipt form

Current Contact Details:
Institutional Ethics Committee (IEC),
New UG/PG Hostel, 20th Storey hostel building, ground floor, KEM Hospital Campus, near main boy’s hostel, Parel, Mumbai 400 012.

Telephone no. (GSMC and KEMH): 91 22 410 7000 Ext. 7515, 24107515, 24122188
Email: iec-1@kem.edu and iec-2@kem.edu

Annexure 5
AX 05/SOP 05/V5
Guidelines for Investigators

1. All the studies qualifying as ‘clinical research’ need to be submitted for the Institutional Ethics Committees review.

2. An Investigator planning to conduct a research study involving human participants; funded by Government agencies and Pharmaceutical companies at Seth G.S. Medical College & K.E.M. Hospital will need an approval by the Institutional Ethics Committee (IEC) before commencing a study..

Research studies which are undertaken as dissertation projects (postgraduate students: MD, MS, MCh, DM, DNB, PhD, MSc, MPTh, MOTH, Nursing), research projects of undergraduate students (Indian Council for Medical research studentship) and investigator initiated research studies which are self funded and those funded by Research Society of KEM Hospital, Diamond jubilee Society trust will need an approval by the Institutional Ethics Committee (IEC) before commencing a study.

3. Location and Office Address (current):
   Institutional Ethics Committee (IEC),
   New UG/PG Hostel, 20 Storey hostel building, ground floor, KEM Hospital Campus, near main boy’s hostel, Parel, Mumbai 400 012. Telephone no. (GSMC and KEMH): 91 22 410 7000 Ext. 7515, 24107515, 24122188, Email: iec-1@kem.edu and iec-2@kem.edu

The IEC office hours for submission of documents, enquiries and telephonic communication with the IEC staff are as follows:
   Monday to Friday - 1.30 p.m. to 4.00 p.m.
   Saturday - 10.30 a.m. to 12.00 noon

The office will remain closed on Sundays, all public holidays and last working day of every month.

4. There will be no meetings held in the month of May and November (during college vacations). In case a meeting is to be held during vacation due to unavoidable reasons, the decision will be taken by the Member Secretary in consultation with Chairperson.

5. The clinical trial (Any investigation in human research participants intended to discover or verify the clinical, pharmacological, and/or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s), and/or to study
absorption, distribution, metabolism, and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy [ICH-GCP]) must be registered with the Clinical Trial Registry of India (CTRI) or any other WHO platform registry and a copy of the documentation of registration must be provided at the time of submission of a new study proposal for review.

6. General responsibilities of PI and Co-PI

- **MRC:**
  Investigators involved in the trial are competent having a valid medical degree registered with the Medical Council of India (MCI) / State Medical Council or a dental degree registered with the Dental Council of India / State Dental Councils.

- **Updated CVs:**
  Investigators responsible for conduct of clinical trials are adequately qualified, experience.

- **GCP:**
  Investigators are knowledgeable in trial process, ethical issue and applicable rules and regulation ensuring data integrity and protection of subject rights, safety and wellbeing.

  Investigators should be GCP trained regularly at the interval of three years and GCP training certificate should be provided to the IEC at the time of submission of a new study proposal / prior to initiation as applicable.

- **SOPs of IECs:**
  Investigators should follow documented procedure i.e. Standard Operating Procedures (SOPs) of IEC in compliance with the regulation and the approved protocol or informed consent, safety reporting management, delegation of responsibilities and training, investigational product, clinical trial documentation, record retention, archival and destruction.

- **Investigators site specific SOPs for regulatory studies:**
  Investigator should prepare the site specific SOPs which should be approved by the IEC and one copy should be handed over to the IEC for IEC records. Site specific SOPs should also cover the following elements related to the conduct of the clinical trial.

  a. Updated investigators Brochure and clinical trial oversight plan
  b. Work delegation log signed by the PI
  c. SOP/Policy document to ensure continuity of trial in case of staff and investigator attrition
  d. Clinical trial site shall have a policy of investigators handling over the trial case he /she to leave investigator will continue to be responsible for the trial until such time another investigator takes over the trial. Authorized person from the site shall communicate with the
6. The IEC is currently following the version 5 dated 26th July 2017 of the Standard Operating Procedures (SOPs), which are individual activity based and are 20 in number. The SOPs are available at our website www.kem.edu.

7. The following steps need to be followed by investigators while submission of a New study proposal to the IEC:

   I Prior to approval of a research study
   a) e-EC software registration for the Principal Investigator:

      • PI should keep ready following information and documents (in PDF versions) at the time of registration:
        1. Employee / Student ID Numbers of study team
        2. Current Medical Council Registration certificate
        3. Passport size photo
        4. Biodata
        5. GCP training Certificate (within the preceding five three years)

      • Follow the link as http://iecmanager.org
        1. Select institution as Seth GS Medical College and KEM Hospital, Mumbai.
        2. Register

       3. Submit the required information (registration) to get associated with institution for the project submission under following heads.
          a. Basic information
          b. Professional information
          c. Certifications
          d. Trainings
          e. Submit (Request)

       o Principal Investigator registration request will set for IEC Admin verification. After IEC admin approval, user will get the account activation link to his/her email. Through this he/she can set their own password to login to system as Principal Investigator(PI).

      Note: Only PI can forward the Project to IEC Admin.

      Project proposals submitted via e-EC on or before 20th of every month till 24.00 am will usually be taken up for discussion at the next month’s IEC meeting.

b) The investigator should ensure that there is an ‘Ethics Section’ in the protocol which is in compliance with the ICMR 2006 Guidelines. The section should include the following aspects which may be stated in the Ethics Section or elsewhere in the protocol:

   ➢ A statement saying that the study will be conducted in adherence to relevant national/international laws.
   ➢ Policy regarding autonomy (voluntariness, right to withdraw).
   ➢ Confidentiality
   ➢ Recruitment policy ensuring equitable enrollment.
   ➢ Protection of vulnerable participants.
Management of Initial Protocol Submissions

- Process of obtaining informed consent.
- Policy regarding treatment of study related injury, compensation for study related injury and compensation for participation.
- Policy regarding dissemination of data, presentation of data, publication.

c) Incompletely filled forms / forms without signatures / proposals will not be accepted and same will be conveyed to the PI.

d) Decision on type of review:
   Member secretary will review the protocol and related documents and will take the decision regarding the type of the review required for the particular protocol as follows:
   a) Full Board Review (refer SOP XXXX)
   b) Expedited Review (refer SOP XXXX)
   c) Exempt from Review (refer SOP XXXX)

e) An investigator may refer to the SOP. No. 23 for ‘Request for Waiver of Written Informed Consent’ whenever necessary.

f) An investigator is required to refer to the format of an Informed Consent Document for genetic study whenever applicable AX 07/SOP 05/V5

For all projects sponsored by pharmaceuticals, the processing fees will be total of Rs. 60,000/project + Taxes, for the Government sponsored projects, the processing fees will be Rs. 7,000/project and for all academic (non-sponsored) projects the processing fees will be Rs. 1,500/-project (in hard cash). The processing fees shall be collected only once at the time of submission of the project. The sponsored projects fees will be accepted by cheque / demand draft which will include the tax, drawn in the name of ‘Diamond Jubilee Society Trust, Seth G. S. Medical College’. The funds of the IEC are maintained in the Diamond Jubilee Society Trust (DJST) account, PAN no. AABTS5336G.

Duplicate copy of any document (for e.g. Permission letter, certificate, query letter) will be charged Rs. 200/-).

g) An investigator may be invited (telephonically/ through written communication) to the IEC meeting to discuss issues related to the study proposal.

h) Investigator will be able to track the status of the submitted project and respective meetings dates on PI’s dashboard of e-EC software.

i) For clinical study planned on an “alternative system of medicine” (Ayurveda, Homeopathy, Siddha, Unani), a Co-Investigator/ Collaborator from that system should be included in the study team. The co-investigator appointed should be independent and he/she should not have a conflict of interest with the study, investigator or sponsor. This is in accordance with the ICMR 2006 guidelines.

j) An investigator is expected to submit reply to the letter of recommendations/ queries sent by the IEC within 180 days of date of receipt of the letter. In the absence of any response, the project will be declared closed for the IEC office records. The documents for these projects will be shredded by IEC staff and same will be recorded in the log book for shredded documents.

II Once approval for a study is granted

a) An approval will be granted for the entire duration of the study.
b) It is the responsibility of the principle investigator that for studies which will continue for more than a year, a continuing review report needs to be submitted (within 1 month of the due date i.e. 11 months from the date of approval).

For all projects sponsored by pharmaceuticals, the annual continuing review fees will be Rs. 10,000/project (approved in 3rd September 2014 minutes), for the Government sponsored projects, the processing fees will be Rs. 1,000/project (approved in 3rd September 2014 minutes). For academic (non-sponsored) projects (in hard cash) no continuing review fee will be charged (approved in 3rd September 2014 minutes). The continuing review fees shall be collected every 11 months from the date of approval (unless specified otherwise). The sponsored continuing review fees will be accepted by cheque / demand draft which will include the tax, drawn in the name of ‘Diamond Jubilee Society Trust, Seth G. S. Medical College’. The funds of the IEC are maintained in the Diamond Jubilee Society Trust (DJST) account, PAN no. AABTS5336G.

c) Submission of Study Related Documents for IEC review

Study related documents (protocol amendments, SAE reports, status reports, study completion reports, protocol deviations/violations) will be accepted during the office hours specified above. Only one set of the above stated study related documents need to be submitted for the IEC review.

Agenda for the IEC meeting is prepared 3 days in advance before the date of meeting and is sent to the IEC members at least 2 days in advance. Hence the study related documents like answers to the IEC queries and amended study related documents (Protocol, ICD, CRF and IB) received within seven days and other types of documents within 3 days preceding the date of meeting will not be considered for the meeting. It will be deferred to the next month’s meeting for discussion (Exception - any matter which in the opinion of the IEC secretariat has direct bearing on the safety of the research participants such as SAE report, major protocol violation).

d) Submission of Amended Protocol and Protocol Related Documents

All amendments to the approved research proposal (only one set) should be submitted to the committee for its review no later than 7 seven days prior to the date of forthcoming meeting.

No changes in the protocol, case record form and/or Informed Consent Document shall be initiated without prior written approval from the committee, except when necessary to eliminate immediate hazards to the research participants, or when the change(s) involve only logistical or administrative aspects of the trial (e.g. change of monitor(s), telephone number(s).

A covering letter should be submitted mentioning reason/s for amendments and summary of changes and the amended text must be highlighted in the revised Protocol and Protocol Related Documents.

e) Submission of Report of Protocol Deviations/ Violations in the study protocol Please use 1- Deviation / Non-Compliance / Violation Record AX 01/SOP 12/V5 for submitting report of Protocol Deviations/ Non-Compliance / Violations.

f) Submission of Report of Serious Adverse Events (SAEs)

The Principal Investigator should submit within 24 hours on site SAE report or the unexpected adverse event report as per the format specified in AX 01/SOP 14/V5 (Appendix XI of Schedule Y) and AX 02/SOP 14/V5 to the IEC or by email. The report of SAE of death after due analysis shall be forwarded by the Investigator to chairman of the IEC and Chairman of the Expert Committee constituted by the Licensing Authority under Appendix XII with a copy of the report to the
Licensing Authority and the head of the institution where the trial is been conducted within 10 calendar days of SAE of death. The report of the SAE other than death after due analysis shall be forwarded by the Investigator to Licensing Authority, chairman of the IEC and the head of the institution where the trial is been conducted within 10 calendar days of occurrence of SAE.

The SAE report should be accompanied by detailed narrative of the SAE and CIOMS form. It should be submitted as per checklist detailed by Licensing Authority in (Annexure A) and given in AX 01/SOP 14/V5.

The sponsor or his representative shall pay the compensation in case of clinical trial related injury or death within 30 days of the receipt of such an order from Licensing Authority.

g) Any new information that may adversely affect the safety of the research participants or conduct of the trial should be informed to the IEC.

h) If an investigator wishes to appeal against the decision about rejection of a research proposal by the IEC, please contact the IEC and submit your appeal in writing, addressed to the IEC Chairperson with justification relevant to the issues/ objections raised by the committee within twelve (12) weeks of the receipt of the committee’s decision. In absence of appeal, the project will be declared closed for the IEC office records.

i) Submission of continuing review report in case of studies which continues for more than a year.

- For studies which will continue for more than a year, a continuing review report as per the format AX 02/SOP 10/V5 will need to be submitted for review
- If the Principal Investigator fails to submit the continuing review report within one month of the due date (i.e. 11th months from the date of approval, unless specified otherwise), the IEC secretariat will send a reminder as per the format AX 01/SOP 10/V5 within 7 working days of this due date. If there is no response within 15 days after the date of reminder, the IEC secretariat will put up the matter for discussion at the forthcoming full board meeting for appropriate action which may consist of but not limited to:
  a) A letter of reprimanding the Investigator
  b) Not reviewing future projects from the PI for a specified period of time
  c) A letter asking the Investigator to put recruitment of new participants on hold

III Once a study is over

Submission of Study Completion Report

For studies which are completed within the IEC approval period, a study completion report as per the format given in AX 01/SOP 11/V5 should be submitted to the IEC, by the investigator. The study completion report is expected for review within 1 month of completion of the study at the site. A brief study report containing data analysis from all centres should be submitted once available from the sponsor.

IV In case a study is not initiated or terminated, the same should be communicated to the IEC stating reasons for the same. The format for submission of report of premature termination of the study is as per AX 01/SOP 13/V5 should be used

1. The IEC archives all the study related documents for a period of 5 years after the study is completed / terminated/ reported as not initiated at our site. In case, an investigator needs a copy of any
document submitted to the IEC, a written request can be made for retrieval of the same using the form1- Document Request Form AX 01/SOP 19/V5

Sponsor responsibilities

Any report of serious adverse event or death occurring in clinical trial after due analysis shall be forwarded by the sponsor to the chairman of the IEC and the head of the institution where the trial is been conducted within ten calendar days of occurrence of the SAE or death. The report of the SAE other than death after due analysis shall be forwarded to chairman of the IEC and the head of the institution.

In case of injury or death occurring trial subject the sponsor (whether a pharmaceutical company or an institution) or his representative, whosoever had obtained permission from the Licensing Authority for conduct of the clinical trial shall make payments for medical management of the subject and also provide financial compensation for the clinical trial related injury or death in the manner as prescribed in SOP 5 Annexure 6.

Appendix I: Regulatory permissions

• DCG(I) approval

Studies which plan to use a new drug (as defined in 122-E of the Drugs and Cosmetics Act, 1945) require DCG (I) permission. For such studies, a copy of the permission letter issued by the DCG (I) to the pharmaceutical company/investigator also needs to be submitted to the IEC. If the DCG (I) permission is awaited, a letter of provisional ‘approval will be issued by the IEC and the final IEC approval will be given after a copy of DCG(I) permission is submitted to the IEC. No study should be initiated until the final letter of permission is issued by the IEC.

• FDA marketing/manufacturing license for Ayurvedic/ herbal formulations/ nutraceutics

• Health Ministry Screening Committee (HMSC) approval in case a study involves collaboration with any foreign laboratory/clinic/institution

• Bhabha Atomic Research Centre (BARC) approval in case a study involves use of radioisotopes/ ionizing radiations

• Genetic Engineering Advisory Committee (GEAC) approval in case a study involves use of gene therapy

• Administrative sanction from the head of the Institution should be sought by investigators for studies involving collaboration with other Indian or foreign Laboratory/ Clinic/Institution.

• Administration sanction from the head of the Institution for sending the samples to laboratories outside KEM Hospital.

• It is mandatory as per the directive by the DCGI (w.e.f.15th June 2009, which is applicable for clinical trials initiated after 15th June 2009) to register clinical trial at ICMR clinical trial registry at www.ctri.in before enrolling first patient in the study. (Registration is mandatory for interventional clinical trials)

Appendix II: List of forms required for submission of study related documents

The following forms are available in the IEC office and should be used for submission of study protocol and other study related documents as per revised SOPs of the IEC:

• Project Submission Application Form for Initial Review AX 1-A/SOP 05/V5 / AX 1-B/SOP 05/V5
• Checklist of Protocol submission AX 02/SOP 05/V5
• Serious Adverse Event Report Assessment Form for SAE at our site AX 01/SOP 11/V5
• Deviation / Non-Compliance / Violation Record AX 01/SOP 10/V5
• Continuing Review Report Form AX 01/SOP 07/V5
• Study Completion Report AX 01/SOP 08/V5
• Premature Termination Report AX 01/SOP 09/V5
• Document Request Form AX 01/SOP 16/V5
• Guidance document for Department Review Boards (AX 08/SOP 05/V5)
• AV consent checklist for participants (SOP 12, AX02/SOP12/V5)

Submission of Projects for IEC Review

Submission of project proposal by Investigator [as per checklist –AX 02/SOP 05/V5]
(Sponsored by Pharmaceutical companies and Government Organizations)
[Till 20th of every month eg. 20th June]

Documents checked by the Administrative officer

Complete

Received by IEC

1st Review

Incomplete

Received by IEC

Review by the IEC members by circulation of projects [about 4 weeks] and
Discussion at full board meeting [3rd / 4th week of the next month eg. 3rd week of July]

Decision communicated to investigator [within 14 days of meeting eg. 1st week of August]
(Approval/Disapproval with reasons/ Modifications in the proposal)

Submission of response to IEC queries/modified project documents
[to be submitted within 180 days after the IEC query letter is sent ]

2nd Review

Member

Secretary/ Chairperson,

informed to members

two/more designated members,
informed to members at full board

Institutional Ethics Committee (IEC)
Seth G.S. Medical College and K.E.M. Hospital,
Parel, Mumbai – 400 012.
Web: www.kem.edu
Management of Initial Protocol Submissions

SOP 05/V5
Effective from 1st Aug 2017
Valid up to 30th July 2019
Management of initial Protocol Submissions

at full board meeting
Full Board discussion meeting

Decision communicated to investigator [within 14 days of meeting eg. 1st week of August]
(Approval/Disapproval with reasons/ Modifications in the proposal)

3rd / Subsequent Review Procedures- Similar to 2nd Review

Annexure 6
AX 06/SOP 05/V5
Sample Format of an Informed consent document in English (This template should be customized according to the requirement of individual research project)

I Project title:
To test the efficacy and tolerability of XXXXXXXX (an antihypertensive test drug) as compared to XXXXX (a standard antihypertensive drug)

II Introduction:
You are invited to participate in a research study. It is important that you read this description of the study and understand your role in it including the nature and risks of participation.
Please give your consent to participate in this clinical study only if you have completely understood the nature and course of this study and if you are aware of your rights as a participant.

III Purpose of the study:
It is well known that people who suffer from high blood pressure are at high risk for cardiovascular disease, including heart attacks, strokes and even death. Anti-hypertensive medications are commonly prescribed to such patients to prevent the occurrence of cardiovascular events. XXXX is a new drug, which has been found to decrease the blood pressure in initial studies. The study plans to study the efficacy and safety of this drug in patients having high blood pressure.

IV Expected duration of the study and number of research participants:
You will be one of approximately XXX people who will participate in this study. You will be in the study for about XXX days. (If multicentric study – mention that the study is also being carried out at xxx other centers).

V Study procedures to be followed:
If you agree to participate in this study you will a) be asked about previous medical problems, your current health and your medications; b) have a brief physical examination (to give details); c) need to undergo baseline investigation such as XXXXXXX (to give details)
The study staff will review the results of these evaluations & test. If you are eligible to participate you will be randomly assigned (like the flip of a coin) to a study group to receive one of the two study treatments.

The study would require a total of XX visits. At each visit XX ml (mention 1-2 tsp/tbsp as applicable) of your blood will be withdrawn after fasting for XX hours. The blood samples that are drawn, will be used to check your blood sugar levels, kidney and liver function etc. (mention whatever is applicable).

Regardless of the group to which you have been assigned, you will return to the study centre after XXXX days / weeks / months. It is important that you bring all of your study medications, diary etc. along with you.

At each visit, a) you will be asked about your health, side effects of medications, b) your physical examination will be carried out c) you will be given a new supply of study drug.

VI Risks and discomforts of participating:

The study testing 2 different therapies in high risk people that may prevent heart attacks, strokes or death from cardiovascular causes:

Based on studies in animals and other studies with people, the drug(s) used in this study may cause some side effects. The known risks and side effects associated with the drugs proposed for use here are summarized below.

Side effects of test drug – XXXXX (Give Details) (for interventional trial)

Side effects of standard drug – XXXXX (Give Details) (for interventional trial)

Other side effects that you may experience could include injection site reactions, allergic reactions to the medication, itching rash and pain at the injection site (if the drug is to be administered parenterally). While collecting blood from your vein, you will have to undergo the discomfort of brief pain or rarely develop bruising or even a minor infection. In case this occurs appropriate management will be provided.

Finally new problems or side effects other than those that have been seen before could occur during this study. You will therefore be asked about side effects at each visit. It is important that you report any of the side effects described in this form or any other ones to the study physician immediately at the numbers listed below.

Because the safety of the study drugs for an unborn fetus or newborn is unknown, if you intend to become pregnant, are pregnant or are breastfeeding you cannot participate in this study. If you are a woman who is able to have children, you will be required to undergo a urine pregnancy test. If you are no pregnant you will be asked to take precautions to prevent pregnancy until the end of the study. The doctors will discuss the contraception options with you. Pregnancy test may be repeated during the study. If you become pregnant despite these precautions you should immediately notify the study team. Pregnancy will be a reason to stop study treatment.

Any new important information that is discovered during the study and which may influence your decision to continue in the study will be provided to you or your legally acceptable representative in a timely manner. You will be told of any new risks or side effects.

VII Possible benefits of the study:
By participating in this study, you may have a possible cure or improvement in your condition. However, there is no guarantee that you will receive direct health benefit from being in this study. Your participation in this study may provide information that may in the future help other patients suffering from high blood pressure.

VIII  What happens when the research trials stops?

Because this is a research trial, the test drug will not be available at the end of this trial for treatment of this disease. Alternate therapy, if appropriate, will be provided once the trial is finished. Occasionally the company sponsoring the research may stop the study early – if this occurs the reason(s) will be explained to you.

IX  Compensation for participation:

Participation in this study will be at no cost to you. The medication and clinic visits will be provided free of charge. No compensation will be provided for your participation. Payment for things such as lost wages is not available. (Wherever applicable give details e.g. reasonable travel assistance will be provided for your participation etc.)

X  Treatment and Compensation for study related injury: (for interventional trial)

You will be provided medical treatment at this institute for any physical injury or illness that occurs as a direct result of your participation in this study. This medical treatment will be at no cost to you. The study doctor/sponsor will compensate anyone in case there is temporary/permanent disability or death as a direct result of participation in this trial. In case of death, their dependents are entitled to material compensation. (provision of insurance coverage by the sponsor for study related injury, if available, may be stated here). You will not give up any of your legal rights by signing this form.

Any injury or death of the participant occurring in clinical trial due to following reasons shall be considered as clinical trial related injury or death and the subject or his/her nominee(s) as the case can be are entitled for financial compensation:

a) adverse effect of investigational product(s)
b) violation of the approved protocol, scientific misconduct by the sponsor or the investigator.
c) failure of the investigational product to provide intended therapeutic effect
d) use of placebo
e) Adverse effects due to concomitant medication excluding standard care, necessitated as part of approved protocol.
f) for injury to child in utero because of the parents participation in the trial
g) any clinical trial procedure involved in the study.

[Paragraph from ICMR 2006 guidelines –
Obligation of the sponsor to pay: The sponsor whether a pharmaceutical company, government, or an institution, should agree, before the research begins, in the a priori agreement to provide compensation for any physical or psychological injury for which participants are entitled or agree to provide insurance coverage for an unforeseen injury whenever possible.]

[As per the notification from the office of DCGI (Notification GSR NO 53 (E) Dated 30-01-2013, 122 DAB), it is mandatory for the sponsors to comply the following requirement:}
A. “In event of any injury occurring to the clinical trial subject, such subject shall be provided free medical management as long as required.
In the event of a trial related injury or death, the sponsor or his representative should provide financial compensation for the injury or death. The financial compensation will be over and above any expenses incurred on the medical management of the subject.
In case of clinical trial related death of the subject, his/her nominee(s) would be entitled for financial compensation as per the order of the Licensing Authority and same should be included in Patient Information Sheet / Informed Consent Form”.

B. Date of Birth /Age ..........
Address of the subject.............
Qualification.................
Occupation- student/self-employed/service/housewife/other (please tick as appropriate)
Annual income of the subject ...........
Name and address of the nominee(s) and his relation to the subject ...........
(for the purpose of compensation in case of trial related death)
C. Name of the witness .................
(copy of the Patient information sheet and duly filled ICF shall be handed over to the participant or his/her attendant)

XI Right to withdraw from the study:
Participation in this study is entirely voluntary. You may choose not to take part or you may leave the study at any time. Your decision will not affect your further treatment at this institute. If you decide to leave the study, you may have to undergo some tests and/or procedures, which will be done to protect your safety.

XII Confidentiality:
All study records will be kept confidential at all times. Your identity will not be revealed except as required by law, DSMB and IEC. The results of your treatment (details: laboratory tests, photographs, x-rays etc.) may be published for scientific reasons. Your identity will not be revealed in these publications.

XIII Contact for further information:
Thank you for taking the time to read (or have read to you) the information about this study. Before you sign this document, you should ask questions about anything that you do not understand. The study staff will answer questions before, during & after the study.
If you have questions about this study or how it is being run, drug side effects or a possible research related illness or injury, you can contact the study doctor XXXXXXX, designation, department XXXXXXXX at telephone number XXXXXX during the office hours, or at XXXXX at outside office hours.
If you have any questions about your rights as a research participant, or complaints regarding the research study, you should call XXXXXXX who is the Member Secretary of Institutional Ethics Committee on the following telephone number on working days. Tel. no.: 91 22 2410 7000, Ext. 7515, 91 22 24107515, 91 22 24122188 (Monday to Friday- 9:00am to 4:00pm; Saturday-9:00am to 1:00pm).

XIV Consent:
I have read or have had read to me the information given in the Informed Consent Document for this study entitled “XXXXXXX”.

I have received an explanation of the nature, purpose, duration, and foreseeable effects and risks of the trial and what I will be expected to do. My questions have been answered satisfactorily.

I understand that my participation in the trial is voluntary and that I may refuse to participate or may withdraw from the trial at any time, without penalty or loss of benefits to which am otherwise entitled.

I further understand that any information that becomes available during the course of the study that may affect my willingness to take part will be informed to me.

Institutional Ethics Committee authorities may wish to examine my medical records to verify the information collected. By signing this document, I give permission for this review of my records.

I understand that my identity will not be revealed in any report or publication.

I agree to take part in the above study.

Name of research participants  Signature/ thumb impression of research participants  Date

Name of Legal Representative (LAR)  Relation to research participants  Signature / Thumb Impression of LAR  Date

Name of the Impartial Witness  Signature of the Impartial Witness  Date

Name of the person Administering consent  Signature of the person administering consent  Date

PLEASE NOTE THAT THE INFORMED CONSENT DOCUMENT SHOULD HAVE PAGE NUMBERS

Annexure 7
AX 07/SOP 05/V5
Sample Format of an Assent to be a Participant in a Research Study
(For Children between 7-18 years old) in English
(This template should be customized according to the requirement of individual research project)
1. **What do we wish to tell you?**

I am Dr. ___________________. We want to tell you about something we are doing called a research study. A research study is when doctors collect a lot of information to learn more about something related to health and disease.

After we tell/explain you about it, we will ask if you'd like to be in this study or not.

2. **Why are we doing this study?**

We want to find out

So we are getting information from ................... boys and girls of your age.

3. **What will happen to you if you are in this study?**

Only if you agree, two things will happen:

(as applicable to research study)

1. A small amount of your blood will be drawn. That means it will be taken by a needle in your arm. This will happen......times. [If some or all of blood draws would be done anyway as part of child's clinical care, emphasize here what will be done extra for the study.]

2. The doctors will do some tests on ............
3. You will need to answer some questions about ............
4. You will be given a medicine .............(explain as applicable)
4. Is this bad or dangerous for you to get involved in this research? Will this study hurt? (explain risks involved as applicable)
The stick from the needle to draw your blood will hurt, but it will soon disappear.
5. How will this research study be useful to you?
No, this study won't make you feel better or get well. But the doctors might find out something that will help other children like you later.
6. Will everybody come to know about your condition? (Confidentiality)
We will not tell other people that you are in this research and we won't share information about you to anyone who does not work in the research study.
7. Do you get anything for being in the research?
[Mention any reimbursements or small gifts/incentives]
8. Will you tell me the results?
[Include details if relevant. Also inform about possibility of publication and keeping confidentiality in publication]
9. Do you have any questions?
You can ask questions any time. You can ask now. You can ask later. You can talk to me or you can talk to someone else.
10. Do you have to be in this study?
No, you don't. No one will be force you if you don't want to do this. If you don't want to be in this study, just tell us. And remember, you can say yes now and change your mind later. It's up to you. This will not affect in any way your future treatment in this hospital.
11. Who can you talk to or ask questions to?
[Contact information for those people who the child can contact easily (a local person who can actually be contacted). Tell the child that they can also talk to anyone they want to about this (their own doctor, a family friend, a teacher).]

12. **Signature of Person Conducting Assent Discussion**
I have explained the study to ______________________(print name of child here) in language he/she can understand, and the child has agreed to be in the study.

______________________________  _________________________
Signature of Person Conducting Assent Discussion Date  

______________________________  _________________________
Name of Person Conducting Assent Discussion (print)  

**Assent Statement**
I have read this information (or had the information read to me) I have had my questions answered and know that I can ask questions later if I have them.
I agree to take part in the research.
Name of child ___________  Signature of child: ________________
Date: ________________  

**OR**
I do not wish to take part in the research and I have not signed the assent below. ___________  
(initialed by child/minor)
I have witnessed the accurate reading of the assent form to the child, and the individual has had the opportunity to ask questions. I confirm that the individual has given consent freely. [in case of illiterate child]
Name of witness (not a parent)_________________  and
Thumb print of participant
Signature of Witness ______________________
Date ______________________
Name of Investigator ---------------------------------
Signature of Investigator ____________ Date : -----------------

(Copies of the Child information sheet and duly filled and signed ICFs of child and parent shall be
danded over to the participant or his/her attendant)

Annexure 8

AX 08/SOP 05/V5

Format for Informed Consent Document for Genetic Studies

This document will, in general, follow the format of the informed consent document contained in
Annexure 4 of SOP no. S AX 04/SOP 05/V5. The additional specific components related to genetic
studies are elucidated here.

These guidelines are meant to provide assistance in framing informed consent documents for
genetic research studies. The examples given may be inserted, where relevant, by the
investigator/sponsor.

A. Project Title and Purpose of the Study

Given the more complex nature of genetic research, the sponsor/investigator should make the
nature of the research abundantly clear to the research participant. The sponsor/investigator should
also generally define genetic/genomic research in the context of the study under consideration in
layman’s terms. If the investigator so desires, a glossary of genetic terms used may also be provided.

Example:

1. The purpose of this document is to enable you to understand the nature of the research that we
   are undertaking. Do take time to review this document IEC fully and do not hesitate to ask the
   investigator any question or clarification related to the research.

2. This study involves the analysis of how genes, blood components or DNA relate to the way that
   investigational therapies are absorbed, broken down and eliminated from the body, how they
   affect the body and how DNA relates to human disease.”

B. Study Procedures to be followed

The sponsor/investigator should explain in layman’s terms the procedure to obtain any genetic
material/tissue from a research participant.

C. Risks and Discomforts

The sponsor/investigator must explain the risks involved in the procedures to obtain any genetic
material/tissue. Separate risks relating to genetic information obtained should also be explained.

Example: “There is a chance that participation in this study could cause psychological distress, social
and economic harm either to you individually or to your community.”

D. Possible benefits of the study

The sponsor/investigator ought to mention benefits if any that may accrue to the participants/community. If no such benefits are seen/ guaranteed at this point in time, the same
may be explicitly stated. However, if there is a possibility of long-term societal benefits, this should
be incorporated. The sponsor should also state his/her policy regarding commercial benefit to participant/community.

**E. What happens when the research trial stops?**

The storage of samples, the duration of such storage, the method of destruction of such samples should be stated. The possibility, if any, of using such samples in the future by the same or different investigators should be mentioned. Also, if the genetic study is being carried out as a sub-study, it ought to be stated that stoppage of the genetic study would not result in automatic cessation of the main study. If the study is stopped before schedule and the data is not anonymised, the option of knowing the results of the study should be made available to the research participant. Moreover, if the results of the study indicate that there might be implications for the participant, as regards future medical conditions; appropriate counseling ought to be provided. For example, the necessity of avoiding certain drugs in the future should be explained.

The genetic studies are often carried out as part of basic research and the data generated in initial studies is inadequate. It may inappropriate to use the preliminary data in management of patient’s condition. This aspect needs to be explained (whenever applicable).

Example: *These analyses are done as part of basic research. Basic research analyses are performed under conditions that are different from routine laboratory testing that your doctor may do. Therefore, it would not generally be appropriate for your doctor to use these results as part of your IEC.”*

**F. Compensation for participation and Treatment and Compensation for study related injury**

The provisions of the earlier format contained in Annexure 4 of SOP no. 5 (AX 04/SOP 05/V5) are applicable.

**G. Right to withdraw from the study**

If the genetic study is being carried on as a sub-study, withdrawal from the genetic study should not affect participation in the main study. The participant should be given the right to request for destruction of his/her sample provided the sample has not been anonymised till that time.

**H. Confidentiality**

The participant should be informed whether the samples are to be unidentified, unlinked or coded as defined in the ICMR Guidelines, 2006. If the investigator does not intend to disclose the results of the study (for example, in the case of a preliminary/pilot study), the samples should be ‘anonymous.’

If the investigator intends to disclose the results of the genetic testing, the participant should have the right to decide whether or not he desires such disclosure. Family members are not entitled to know each others’ diagnosis and specific consent is needed from a participant before sharing the information with family members.

Example: *The investigator will provide the genetic analyses to your family, the doctor conducting the main study or any doctor involved in your IEC, your insurance company or your employer, only after obtaining your written consent. However, this is subject to the requirement of disclosure of such information to a court of law. It may also be made accessible to members of the IEC and regulators.”*

---

**Annexure 9**

**AX 09/SOP 05/V5**

**Departmental Review Board (DRB) Guidance Document**

---

Page 44 of 48
Purpose:
To facilitate the review process for the investigators in term of time.

Composition:
- The DRB will be established by the Head of the Department.
- There will be one Chairperson. A Co-Chairperson may be appointed amongst the members (The Co-chairperson will perform the functions of Chairperson in his/her absence).
- The DRB will be composed of at least 3 and a maximum of 7 members.

Details instructions:
The board should give opinion on the scientific aspects of the proposal. The Board should also consider the feasibility of the proposal and collaboration with any other department if required.

Roles and responsibilities of the DRB members:
- It is the responsibilities of the DRB members to read understand, follow the guidance document.
- The DRB will consist of members who collectively have the experience in research methodology and should have at least ≥5 years experience or > 5 yrs PG teaching experience.
- It is the responsibility of Chairperson of the DRB to send the names of the DRB members to the IEC before 31st August 2013.
- All thesis (MD/MS/Post graduate thesis) will be reviewed and approved by the DRB before submission to Institutional Ethics Committee.
- The signature of the Chairperson/ Co-chairperson of the DRB will be mandatory on the DRB approval letter. Incase DRB approval letter is being issued to the chairperson who is also a principal investigator for the study then the signature of the co-chairperson / any of the DRB member can be obtained on DRB approval letter.
- It is the responsibility of the DRB member to attend DRB Meetings and participate in discussions and deliberations so that appropriate decisions can be arrived at.
- It is the responsibility of the DRB member to review, discuss and consider research Proposals submitted for evaluation.
- It is the responsibility of the DRB member to carry out the work delegated by Chairperson.
- It is the responsibility of the DRB member to assist Chairperson in carrying out DRB work.
Receive submitted packages by PI for initial review:

**Project Overview**

- Clicking on view link on Project list of Projects page, will take user to Project Overview.
- Tabs on Top enable IEC Admin to view and review submission under which the user (IEC Admin) will perform his actions against the project submission:

**Project Summary Tab**

- Under project summary tab, Project summary information on respective project submissions will be shown as following
  - Project Title
  - Project Status
  - Review Type
  - Latest Submission Status
  - Name of PI
  - Date of Submission
  - Insurance Expiry
  - Continuation submission date
  - Sponsor

**Submission List Tab (Tab Next to Project Summary)**

By selecting the appropriate submission user can view the list of submissions submitted for that Project.

- Following are the search filters on Submission list
  - Submission Type
  - Document(s) status
    - List of Submission (Following fields are shown)
      - Submission Type
      - Submitted By
      - Submitted On
      - Status
IEC Admin Review (Tab Next to Project Documents)

Upon review of submission by IEC Admin, if application found to be complete, IEC Admin will enter following details (depends on submission type):

- Processing Fee Paid (Yes/No)
- Hard copy of project for regulatory projects submitted (Yes/No)
- Reviewed by (IEC Staff / Admin Name)
- Project Number (textbox for entering allotted Project Number)
- Insurance Date (Renewal)

IEC Admin Review Actions

Upon Review of submission IEC Admin may choose one of the following action depends on his observations.

- Forward (to IEC MS)
- Return (to PI)
- Save (button)

Forward to IEC

- IEC Admin Review – Assign / Forward to IEC will have following sections:
- Ethic Committee (Dropdown with list of ECs)
  - For Project Initial Submission
    - Manual Assignment
    - If the Institution chooses to assign the project manually and update the required configuration during Institution setup, this will enable IEC Admin to assign the projects to IEC committees manually.
      - IEC Admin will select the Ethic Committee for the project and assign it
    - Auto / Random Assignment
    - If the Institution choose to assign the project automatically and update the required configuration during Institution setup, this will randomly assign project to IEC Committee and display the same to IEC Admin.
For the Reply to Queries or Any other submission of project (Ex: Amendments, Deviation, SAE etc.,)

- Ethic Committee already assigned to Project is shown

- Member Secretary (Auto fill depends on EC selection)
- Comments (textbox)
- Forward (button)
  - Upon forwarding, application will be shown to respective IEC MS project list (set for his review).
  - Upon forwarding the application to IEC, an acknowledgement email is sent to investigator.

Return to Principal Investigator

- IEC Admin Return Submission will have following:
  - Comments
    - IEC Admin can enter the info on incomplete information that need to be submitted.
  - Return
    - Upon Return, Message is sent to PI with comments entered for return of submission. (Application status will be updated to Return (by IEC))